On this page
Back to topLb Pharmaceuticals LBRX
Lb Pharmaceuticals listed on Nasdaq on 12 Sep 2025 and is not in the S&P 500. It is worth $1.3 billion. Its board has 10 directors, 7 of them independent. 3 other officers are on file. At 30 Jun 2026, Deep Track Capital was its largest institutional holder, with 11.7% of the company.
- CEO
- Heather D. Turner
- Chair
- J. Scott Garland
- Listed
- 12 Sep 2025 on Nasdaq
- Headquarters
- New York, NY
- Market cap
- $1.3B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Lb Pharmaceuticals' market cap since September 2025
Marked weeks are changes in the share count, such as a merger, not market moves.
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $1.4B |
| 26 Dec 2025 | $540M |
Download Lb Pharmaceuticals' data as JSON, with the weekly market caps in billions of dollars from 12 Sep 2025.
Board and leadership
Board and officers
Board from the proxy filed 23 Apr 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (10) | |||||
| J. Scott GarlandChairIndependent 路 since 2024 路 Audit, Compensation (chair)Advisor, Google VenturesOther boards: Enliven Therapeutics, Olema Pharmaceuticals, ALX Oncology and Day One Biopharmaceuticals | |||||
| Heather D. TurnerDirector and CEONot independent 路 since 2024Other boards: Terns Pharmaceuticals | |||||
| Robert R. Ruffolo, Jr., Ph.D., D.Sc., D.Eng., F.C.P.P.DirectorIndependent 路 since 2019 路 AuditCorporate Director and Former President of Research and Development, Wyeth Pharmaceuticals, Inc.Other boards: Elicio Therapeutics | |||||
| Rekha HemrajaniDirectorIndependent 路 since 2025 路 Audit (chair), CompensationCorporate DirectorOther boards: ALX Oncology Holdings, MaxCyte and BioAge Labs | |||||
| William P. Kane Jr.DirectorIndependent 路 since 2025 路 CompensationPresident and Chief Executive Officer, Uniquity Bio, Inc. | |||||
| Robert A. LenzDirector | |||||
| Robert A. Lenz, M.D., Ph.D.DirectorIndependent 路 since 2026 路 Nominating and Corporate GovernanceBoard Member, NovaBridge BiosciencesOther boards: NovaBridge Biosciences | |||||
| Rebecca LuseDirectorIndependent 路 since 2023 路 Nominating and Corporate Governance (chair)Managing Director of Deep Track Capital | |||||
| Ran NussbaumDirectorIndependent 路 since 2023 路 Nominating and Corporate GovernanceManaging Partner and Co-Founder, Pontifax | |||||
| Robert R. RuffoloDirector | |||||
| Officers (3) | |||||
| Joseph M. MillerChief Financial OfficerLast filed 14 Sep 2026 | |||||
| Susan Gani KozauerChief Medical OfficerLast filed 24 Sep 2026 | |||||
| Panandiker Kaya Kamlesh PaiChief Commercial OfficerLast filed 11 Dec 2025 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Lb Pharmaceuticals. Where a company has several share classes, the share is of its total value. Stakes are of the shares out at 30 Jun 2026; the count has since grown 13%.
13F filings for the quarter to 30 Jun 2026
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
2 departures and 4 appointments of directors and officers in the last two years.
Events, newest first
- 15 Sep 2026 Susan G. Kozauer appointedChief Medical Officer, effective 14 Sep 2026
- 3 Sep 2026 Joseph M. Miller appointedChief Financial Officer, effective 2 Sep 2026
- 8 Jun 2026 Anna Eramo resignedChief Medical Officer, effective 15 Jun 2026
- 13 Mar 2026 Zachary Prensky did not stand for re-electionMember of the Board
- 4 Mar 2026 Gad Soffer appointedChief Operating and Business Officer
- 4 Mar 2026 Robert A. Lenz appointedDirector, effective 6 Mar 2026
| Date | Event | Filing |
|---|---|---|
| 15 Sep 2026 | Susan G. Kozauer appointedChief Medical Officer, effective 14 Sep 2026 | 8-K |
| 3 Sep 2026 | Joseph M. Miller appointedChief Financial Officer, effective 2 Sep 2026 | 8-K |
| 8 Jun 2026 | Anna Eramo resignedChief Medical Officer, effective 15 Jun 2026 | 8-K |
| 13 Mar 2026 | Zachary Prensky did not stand for re-electionMember of the Board | 8-K |
| 4 Mar 2026 | Gad Soffer appointedChief Operating and Business Officer | 8-K |
| 4 Mar 2026 | Robert A. Lenz appointedDirector, effective 6 Mar 2026 | 8-K |
Not on file: no open-market insider buys or sales in the 12 months to 19 Nov 2026, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.